Welcome to the Hope Bio Blog

As 2026 progresses, so, too, does research exploring Hope Biosciences’ proprietary cellular therapeutics in brain injury. Calendar year 2026 commenced with our cells at work in a Phase II clinical trial in Traumatic Brain Injury (TBI) executed by UTHealth Houston; early summer brought peer-reviewed publication in globe-leading neurology journal Brain of results of another TBI trial using our cells; and as summer presses on, we are delighted to begin manufacturing treatments f

Notes, sources, and more for Stem Cell Revolution's recent deep dive into sports, concussions, and CTE Hopefully, you've already enjoyed the most recent episode of Stem Cell Revolution (SCR), available on YouTube and Spotify. (If you haven't seen it yet, it's available above. Click here for more episodes on an array of topics, and please check back each month when new conversations drop!). This month, Houston is proud to host the World Cup, which makes it the perfect time to

By Jan Shultis During the last few weeks of 2025, Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) received Food and Drug Administration (FDA) authorization to administer Hope Biosciences’ allogeneic (donor) adipose-derived mesenchymal (adult) stem cells (HB-adMSCs) to seven men and women living with Multiple System Atrophy (MSA). As HBRF shared in their announcement, the occasion is noteworthy both for authorization of research in a rar